Materias dentro de su búsqueda.
Mostrando 2,521 - 2,540 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.54s Limitar resultados
  1. 2521
    “…In this phase I study, the safety, pharmacokinetics, and antitumour activity of the HER2-targeted antibody–drug conjugate A166 were evaluated in patients with HER2-expressing advanced solid tumours. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Phase I study of A166, an antibody‒drug conjugate in advanced HER2-expressing solid tumours
  2. 2522
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
  3. 2523
    “…METHODS: HER2-positive breast cancer patients undergoing planned anti-HER2 therapy and nonanthracycline-based chemotherapy were enrolled and subdivided into dual anti-HER2 (trastuzumab plus pertuzumab) group and trastuzumab group. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Longitudinal assessment of cardiac parameters through MRI in breast cancer patients treated with anti-HER2 therapy
  4. 2524
    por Bardia, Aditya, Viale, Giuseppe
    Publicado 2023
    “…Breast cancer has been traditionally classified as either human epidermal growth factor receptor 2 (HER2)-positive or HER2-negative based on immunohistochemistry (IHC) scoring and/or gene amplification. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2-Low Breast Cancer—Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast
  5. 2525
    “…Univariate analysis of KRAS mutations and HER2 expression showed that four subjects with KRAS mutations had excess HER2 expression (P=0.341). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Identification of KRAS mutation and HER2 expression in Indonesian colorectal cancer population: a cross-sectional study
  6. 2526
    “…Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate approved by the FDA in 2013 for advanced HER2-positive breast cancer treatment exhibiting promising clinical benefits. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers
  7. 2527
    “…SIMPLE SUMMARY: HER2-positive breast cancers are usually diagnosed from clinical findings, and often in a large size, with extensive microcalcifications, and/or with axillary involvement, which may compromise conservative surgery, both in the breast and in the axilla. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Surgical Interest of an Accurate Real-World Prediction of Primary Systemic Therapy Response in HER2 Breast Cancers
  8. 2528
    “…BACKGROUND: We aimed to determine the molecular and immune microenvironment characteristics of HER2‐positive gastric cancer (GC) related to the patient's response to first‐line trastuzumab‐based treatment. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Genetic and immune microenvironment characterization of HER2‐positive gastric cancer: Their association with response to trastuzumab‐based treatment
  9. 2529
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Retraction Note: PlncRNA-1 induces apoptosis through the Her-2 pathway in prostate cancer cells
  10. 2530
    “…HER2-positive metastatic breast cancer patients who received long-term trastuzumab were included in the study. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
  11. 2531
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Comparison of Two Chemotherapy Regimens After First-Line Treatment for HER2-Negative Metastatic Gastric Cancer
  12. 2532
    “…Human epidermal growth factor receptor 2 (HER2) gene amplification helps identify breast cancer patients who may respond to targeted anti-HER2 therapy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Deep learning to automatically evaluate HER2 gene amplification status from fluorescence in situ hybridization images
  13. 2533
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Prognosis related genes in HER2+ breast cancer based on weighted gene co-expression network analysis
  14. 2534
    “…We explored accumulated genomic alterations in patients with heavily treated HER2 + metastatic breast cancer enrolled in the KCSG BR18-14/KM10B trial. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancer
  15. 2535
    “…Oncotype Dx Recurrence Score (RS) has been validated in patients with ER + /HER2 − invasive breast carcinoma to estimate patient risk of recurrence and guide the use of adjuvant chemotherapy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    MRI-Based Radiomics Approach Predicts Tumor Recurrence in ER + /HER2 − Early Breast Cancer Patients
  16. 2536
    por Qi, Timothy, Cao, Yanguang
    Publicado 2023
    “…Variability in patient HER2 immunohistochemistry scores influenced responses to lapatinib. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study
  17. 2537
    “…Experience from clinical trials with cyclin D kinase 4/6 (CDK4/6) inhibitors in the setting of hormone receptor–positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) early breast cancer is provided as an illustrative example of risk stratification.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2– breast cancer
  18. 2538
    “…BACKGROUND: Cyclin-dependent kinase 4/6 inhibitor (CDK4/6) therapy plus endocrine therapy (ET) is an effective treatment for patients with hormone receptor-positive/human epidermal receptor 2-negative metastatic breast cancer (HR+/HER2− MBC); however, resistance is common and poorly understood. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer
  19. 2539
    “…Human epidermal growth factor receptor 2 (HER2)-positive breast cancer has a high BM frequency. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Dramatic Recovery of Vision after Trastuzumab Deruxtecan Treatment of HER2-Positive Breast Cancer with Pituitary Metastasis
  20. 2540
    por Markers, Disease
    Publicado 2023
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Retracted: Expression and Clinical Significance of HER2 Gene and DNMT1 in Non-Small-Cell Lung Cancer
Herramientas de búsqueda: RSS